Tiliroside protects against diabetic nephropathy in streptozotocin-induced diabetes rats by attenuating oxidative stress and inflammation

Figure 8 Docking poses and interaction pattern of selected targets. A: Fibronectin; B: Interaction with fibronectin; C: Interleukin-6 (IL-6); D: Interaction with IL-6; E: Tumor necrosis factor-α (TNF-α); F: Interaction with TNF-α; G: Interleukin-1β (IL-1β); H: Interaction with IL-1β; I: Transforming growth factor-beta 1 (TGF-β1); J: Interaction with TGF-β1. The docking pose of targets selected based on the binding affinity and RMSD ≤ 3.0 Å interacted with Tiliroside. TGF-β1: Transforming growth factor-beta 1; TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6; IL-1β: Interleukin-1β.